SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001214659-24-005032
Filing Date
2024-03-22
Accepted
2024-03-22 16:30:33
Documents
17
Period of Report
2024-03-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 o3222418k.htm   iXBRL 8-K 29692
2 EXHIBIT 3.1 ex3_1.htm EX-3.1 1968
3 EXHIBIT 4.1 ex4_1.htm EX-4.1 11889
4 GRAPHIC ex31-001.jpg GRAPHIC 51667
5 GRAPHIC ex31-002.jpg GRAPHIC 133518
  Complete submission text file 0001214659-24-005032.txt   482596

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE alzn-20240322.xsd EX-101.SCH 2991
7 XBRL LABEL FILE alzn-20240322_lab.xml EX-101.LAB 34240
8 XBRL PRESENTATION FILE alzn-20240322_pre.xml EX-101.PRE 22343
20 EXTRACTED XBRL INSTANCE DOCUMENT o3222418k_htm.xml XML 4028
Mailing Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326
Business Address 3500 LENOX RD. NE SUITE 1500 ATLANTA GA 30326 844-722-6333
Alzamend Neuro, Inc. (Filer) CIK: 0001677077 (see all company filings)

IRS No.: 811822909 | State of Incorp.: DE | Fiscal Year End: 0430
Type: 8-K | Act: 34 | File No.: 001-40483 | Film No.: 24775687
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)